Spyre Therapeutics
(NASDAQ) SYRE
Spyre Therapeutics Financials at a Glance
Market Cap
$3.85B
Revenue (TTM)
$90.49M
Net Income (TTM)
$155.20M
EPS (TTM)
$-2.08
P/E Ratio
-23.57
Dividend
$0.00
Beta (Volatility)
0.69 (Low)
Dividend
$0.00
Beta (Volatility)
0.69 (Low)
Price
$51.18
Volume
27,154
Open
$48.98
Price
$51.18
Volume
27,154
Open
$48.98
Previous Close
$51.18
Daily Range
$48.95 - $51.20
52-Week Range
$10.91 - $51.20
Dividend
$0.00
Beta (Volatility)
0.69 (Low)
Price
$51.18
Volume
27,154
Open
$48.98
Previous Close
$51.18
Daily Range
$48.95 - $51.20
52-Week Range
$10.91 - $51.20
SYRE News
SYRE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Spyre Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
102
CEO
Cameron Turtle, PhD
Website
www.spyre.comHeadquarters
Waltham, MA 02453, US
SYRE Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
-2%
Net Income Margin
-2%
Return on Equity
-22%
Return on Capital
-29%
Return on Assets
-20%
Earnings Yield
-4.24%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.85B
Shares Outstanding
78.54M
Volume
27.15K
Short Interest
0.00%
Avg. Volume
733.78K
Financials (TTM)
Gross Profit
$171.65M
Operating Income
$209.56M
EBITDA
$209.56M
Operating Cash Flow
$169.25M
Capital Expenditure
$0.00
Free Cash Flow
$169.25M
Cash & ST Invst.
$756.53M
Total Debt
$0.00
Spyre Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$90.49M
N/A
Gross Profit
$45.25M
N/A
Gross Margin
50.00%
N/A
Market Cap
$3.85B
N/A
Market Cap/Employee
$52.70M
N/A
Employees
73
N/A
Net Income
$62.53M
-11.1%
EBITDA
$62.53M
-2.1%
Quarterly Fundamentals
Net Cash
$756.53M
+25.4%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-19.95%
N/A
Return on Invested Capital
-29.14%
N/A
Free Cash Flow
$44.58M
-19.8%
Operating Cash Flow
$44.58M
-19.8%